Why did SILO's operating expenses surge in Q4 2024?

Silo Pharma's operating expenses for Q4 2024 are not currently available. However, we can infer that the company's increased investment in research and development is a key factor contributing to the rise in operating expenses.

The company has been actively developing its pipeline of novel therapeutics, including SP-26, a ketamine-based implant for chronic pain and fibromyalgia. The initiation of a pharmacokinetic and tolerability study for SP-26 in partnership with AmplifyBio is a significant milestone that requires substantial resources.

Furthermore, Silo Pharma has been conducting various studies for SP-26, including analytical testing, small batch proof-of-concept extrusion trials, manufacturing and production evaluation, and sterilization and dissolution tests, which are likely contributing to the increase in operating expenses.

In addition, the company's focus on developing innovative treatments for conditions like stress-induced psychiatric disorders and chronic pain through novel formulations and drug delivery systems has likely led to increased expenses in areas such as personnel, materials, and overhead.

Overall, the surge in operating expenses for Silo Pharma in Q4 2024 can be attributed to the company's ongoing research and development efforts, particularly in the context of advancing its pipeline of novel therapeutics.